1. The concentration of oxalate in plasma was determined by an isotopic method involving the simultaneous measurement of [14C]oxalate activities in plasma and urine and the concentration of stable oxalate in the urine.
obtained by chemical, enzymic and gas-chromatographic techniques, range from 9 to 29 pmol/l (80-260 pg/lOO ml) (Pernet & Pernet, 1965; Knowles & Hodgkinson, 1972; Thomas & Melon, personal communication) . Measurements from radioisotope data, however, have indicated still lower values. Thus, Elder & Wyngaarden (1960) found the rapidly miscible pool of oxalate in normal adults to range from 39 to 71 pmol(3.5-6.4 mg, expressed as the anhydrous acid), and observed that if this pool is distributed extracellularly then plasma values of about 1.5-3.5 pmol/l (14-32 pg of anhydrous oxalic acid/100 ml) would be anticipated. Still lower values, ranging from 0.5 to 1.2 pmol/l (5-1 1 pg/lOO ml) would be expected if the pool is distributed homogeneously throughout the body water (Wyngaarden & Elder, 1966) . Similar low values, derived from the clearance of ['4C]oxalate, have been proposed by Williams, Johnson & Smith (1971) .
In an attempt to resolve the tenfold difference in plasma oxalate levels, as determined by chemical and isotopic methods, we have estimated the plasma oxalate levels by another isotopic method involving the simultaneous measurement of [14C]oxalate activities in plasma and urine and the concentration of stable oxalate in the urine. Measurements have been made of the exchangeable oxalate pool and of the renal clearance of oxalate in normal adults and patients with calcium oxalate-containing renal stones. The effect of the uricosuric agent, probenecid, on the renal excretion of oxalate has also been examined.
SUBJECTS A N D M E T H O D S
Observations were made on three normal male volunteers and fifteen male patients with recurring calcium oxalate or mixed calcium oxalate-calcium phosphate stones (Table 1) . The purpose of the study was fully explained to the patients and each patient consented to the procedures carried out.
Radioisotope studies
Each subject fasted from 21.00 hours on the day before the investigation until 2 h after administration of the radioisotope, after which normal foods and fluid were allowed. Timed urine collections were made before and after administration of the radioisotope and blood samples were collected into heparinized tubes at the mid-point of each urine collection period.
Uniformly labelled [14C]oxalic acid of high specific radioactivity (45.2 pCi/pmol of oxalic acid, or 359 pCi/mg of oxalic acid dihydrate) was obtained from The Radiochemical Centre, Amersham, England, and 2 pCi was administered intravenously in 2 ml of sterile sodium chloride solution (0.1 5 mol/l) or orally in 250 ml of distilled water containing 0.22 pmol(30 mg) of sodium oxalate.
I4C radioactivity was measured by mixing 4 ml of plasma or urine with a gelled liquidscintillation medium (Oxby & Kirby, 1968) and counted in a Philips, type P.W. 4510/D, automatic liquid-scintillation analyser. Activity was expressed as a percentage of the administered dose of l4C/1itre of plasma or urine, after appropriate correction for quenching and background.
Low-and high-purine diets
effect of probenecid on urine oxalate excretion, is shown in Table 2 .
The composition of the constant low-purine and high-purine diets, used in the studies of the
Analytical methods
Oxalate was determined colorirnetrically and mass concentrations are in terms of anhydrous acid (Hodgkinson & Williams, 1972) . Urate was determined colorirnetrically with phosphotungstic acid parley, 1964), creatinine by automatic colorimetry (Technicon AutoAnalyzer, method N-1 lb) and calcium by atomic-absorption spectrophotometry, using a model SP90 atomic absorption spectrophotometer (Pye Unicam Ltd, Cambridge, England). Urinary calculi were analysed by qualitative or quantitative chemical methods (Hodgkinson, 1971) . Body weights are given in Table 1 . Urine collections terminated after 12 h. [14C]oxalate and the plasma oxalate concentration (1.65 pmolll or 14.8 pg/lOO ml), equalled 58.6 pmol (5.2 mg). The intravenous investigation was repeated at intervals of 6 months and 3 months respectively in patients 2 and 5.
The Table 3 .
Concentration of oxalate in plasma
The concentration of oxalate in the plasma was calculated on the assumption that, at any one time, the specific radioactivity of [14C]oxalate in the plasma was equal to that in the urine. Some typical results obtained on a normal subject are shown inTable 4. In this case, the calculated plasma oxalate varied from 0.70 to2.11 prnol/l(6~3-19-Opg/100 ml) during five consecutive collections, and the mean value was 1.32 pmol/l (11.9 pg/lOO ml). The oxalate clearance, calculated from the plasma oxalate value, ranged from 129 to 357 ml/min with a mean value of 226 ml/min. These values were appreciably higher than the creatinine clearances, which averaged 123 ml/min, and the oxalate/creatinine clearance ratio averaged 1.90. The mean plasma oxalate concentrations obtained in the eighteen subjects are illustrated in Fig. 2 . The three normal men had values ranging from 1-3 to 1-6 pmol/l (1 1.8-14.3 pg/lOO ml) (mean = 1*4pmol/l or 13.0 ,ug/lOO ml). The mean plasma oxalate in patients with renal calculi was 1.73 pmol/l (15.56 pg/lOO ml) (SD = 0.55 pmol/l or 4.98 pg/lOO ml); three patients had values greater than 2.2 pmolll (20 pg/IOO ml).
Examples of the reproducibility of plasma oxalate estimations on the same subject on different occasions can be seen in the two subjects in whom repeat intravenous [l4C1 oxalate studies were carried out (Table 3) .
Renal clearance of oxalate
The renal clearance of oxalate may be calculated from the I4C activities in the plasma and urine or from the concentrations of stable oxalate determined in urine and calculated for plasma, both methods giving identical results. Relation between oxalate clearance and creatinine clearance in the same subject. The broken line indicates the points at which the two clearances are equal. A, Normal subjects; 0 , patients with renal stones. Fig. 2 shows the oxalate clearances in the three normal subjects and fifteen patients. The values ranged from 162 to 358 ml/min (mean = 249 ml/min) in the normal subjects and from 95 to 315 ml/min (mean = 201 ml/min) in the patients. Most of these values were much greater than the corresponding creatinine clearances and the oxalate/creatinine clearance ratio exceeded 1.0 in all cases (Fig. 3a) . The ratio ranged from 1.42 to 2.60 (mean = 1.95) in the normal subjects, compared with values of 1.04 to 2.33 (mean = 1.76) in the patients.
A correlation coefficient of 0.702 was observed between the oxalate and creatinine clearances and this is illustrated in Fig. 3(b) . The relationship was significant at the 1% level.
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Eflect of probenecid on urinary excretion of oxalate
Diurnal variations in the rate of excretion of oxalate and urate by a normal subject (no. 1) over a 24 h period were determined with the subject receiving a controlled low-purine diet. These measurements were repeated on the following day with the addition of oral probenecid [5*3 mmol(1.5 g)] daily in three equal doses at 08.00, 16.00 and 24.00 hours, but no significant change in urate or oxalate excretion was observed (Fig. 4, upper two charts) . The study was repeated on a patient (no. 5) who received 7.0 mmol (2.0 g) of probenecid daily (the maximum recommended dose) but again there was no consistent change in oxalate or urate excretion (Fig. 4, lower two charts) .
Probenccid
Prnbenecid Probenecid (5.3rnrnol/day) In an extended study on normal subject 1, oxalate excretion appeared to fall on the second day of probenecid administration while urate excretion rose and creatinine excretion remained unchanged (Fig. 5, left trace) . The investigation was therefore repeated at a higher dose level l7.0 mmol(2.0 g) daily] and for a longer period (3 days), but no consistent change in oxalate or urate excretion was observed on this occasion (Fig. 5, centre trace) . Finally, the study was repeated on a high-purine diet. In this instance, during probenecid administration there was a substantial increase in urate excretion, accompanied by a fall in urine pH and a rise in calcium excretion but no significant change in oxalate excretion (Fig. 5, right trace) .
DISCUSSION
The cumulative recovery of [14Cloxalate in the urine of six subjects, 24 h after an intravenous dose, averaged 935% (Table 3) , a result which compares favourably with that of Elder & Wyngaarden (1960) who reported a mean recovery of 94% after 36 h in five subjects. Although in the present study only the 14C activity in the urine was measured, previous workers have shown the 14C to be solely in the form of ['4C]~xalateand that after intravenous administration, [14Cloxalate is not metabolized in man (Elder & Wyngaarden, 1960; Wyngaarden & Elder, 1966) .
The estimated volume of distribution of [14C]oxalate in the body, expressed as a percentage of the body weight, averaged 45.18% in eight subjects (Table 3 ). This value corresponds to about 80% of the total body water, as measured by the deuterium oxide method (Edelman, Haley, Schloerb, Shedon, Friis-Hansen, Stoll & Moore, 1952) and suggests that oxalate is not freely diffusible into all body compartments. The permeability of biological membranes to oxalate has not been widely studied but the available evidence suggests that, with the possible exception of the mitochondria1 membrane (Fanburg & Gergely, 1969 , most mammalian membranes are freely permeable (Hodgkinson & Zarembski, 1968) . However, the presence of calcium ions may cause a constraint to the free passage of oxalate, the best known example being the effect of calcium on the intestinal absorption of oxalate (Zarembski & Hodgkinson, 1969) .
The miscible oxalate pool, calculated from the plasma oxalate concentration and the volume of distribution in the body, ranged from 32.3 to 95.6 pmol(2.90-8.60 mg) with a mean value of 53.3 pmol (4.80) mg in the eight subjects (Table 3) . Similar values were observed in three normal subjects by Elder & Wyngaarden (1960) .
The mean concentration of oxalate in our three normal subjects was 1~4pmol/l(13-0pg/100 ml), which agreed well with the mean value of 1.83 pmol/l(16-5 pg/lOO ml) proposed by Williams et al. (1971) on the basis of radioisotope data. Plasma oxalate concentrations in the patients generally resembled those in the normal subjects but a few appeared to be slightly elevated, due, we suspect, to slight impairment of glomerular function, since there is now considerable evidence from other studies that plasma oxalate concentration, like urea or creatinine, is inversely related to glomerular filtration rate (Zarembski, Hodgkinson & Parsons, 1966; Knowles & Hodgkinson, 1972) .
The oxalate/creatinine clearance ratio was greater than 1.0 in all the subjects examined (Fig.  3) . Similar high values have been observed previously in man (Williams et al., 1971) and in the dog (Cattell, Spencer, Taylor & Watts, 1962) and imply a net tubular secretion of oxalate. The latter workers reported that net tubular secretion of oxalate in the dog was abolished by the intravenous infusion of the uricosuric drugs, caronamide or probenecid. The failure of probenecid to alter the urinary excretion of oxalate in human subjects does not appear to be due to the lower dose levels permissible in man, since the dose used is sufficient to inhibit the tubular transport to a variety of organic acids in man, including uric acid (Sirota, Yu & Gutman, 1952) and penicillin (Nichols, Richards & Finland, 1957) , and was sufficient to increase urate excretion in the present study (Fig. 5) . The dose was also sufficient to increase calcium excretion, an effect observed previously by Garcia & Yendt (1970) . Our results therefore suggest that probenecid in the usual therapeutic dosage does not alter the urinary excretion of oxalate in man. The use of probenecid intravenously in the dog by Cattell et al. (1962) was based on the finding of oxalate/creatinine clearance ratios greater than 1.0 and, by implication, a net tubular secretion of oxalate. These results, in turn, imply a plasma oxalate concentration of about 1.1 pmol/l(lO pg/IOO ml). However, if the normal plasma oxalate concentration is about 11.0 pmol/l (100 pg/lOO ml), as indicated by the chemical methods, then the oxalate/creatinine clearance ratio will be less than 1.0 and it becomes unnecessary to invoke net tubular secretion of oxalate. In these circumstances, probenecid would not be expected to affect oxalate excretion.
The discrepancy between plasma oxalate concentrations obtained by radioisotope methods and those obtained by chemical or enzymic methods remains unexplained. Despite many refinements in recent years, the chemical methods still yield values which are approximately 10 times those obtained by isotopic procedures. The chemical values may be too high because of lack of specificity and this may be true also of the enzymic and gas-chromatographic methods. On the other hand, the radioisotope methods may possibly yield low values because of incomplete exchange of ['4C]oxalate with stable oxalate in the body or because of some other artifact. In the present study it was assumed that the specific radioactivity of ['4C]oxalic acid in the plasma was equal to that in the urine at any given time. This assumption can be tested if there is a suitable method available for measuring the stable isotope in plasma and urine, but this was not possible in the present case, for reasons already stated, and it will be of interest to determine the true concentration of oxalate in normal plasma.
